Novo Nordisk shares fall 5.5% after latest trial results for its next-generation weight loss drug
- Posted on March 10, 2025
- By CNBC
- 1 Views
Novo Nordisk shares fall 5.5% after latest trial results for its next-generation weight loss drug
Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its CagriSema weight-loss drug.
